Low-Dose Rapamycin Cuts Immune Cell DNA Damage by 40%

Discover how low-dose rapamycin directly protects immune cell DNA from lethal double-strand breaks and reverses cellular senescence. We break down the landmark 2026 Oxford and Nottingham study published in Aging Cell, along with new biomarker data from a 4-month placebo-controlled human clinical trial (NCT05414292). 🧬 SUPPORT THE CHANNEL & LONGEVITY PARTNERS If you would like to support our channel please consider joining our Patreon https://patreon.com/ModernHealthspan ~~~~~~~~~~~~~~ *Renue By Science* (10% off: MHS) https://tinyurl.com/bdew4bfs NMN Powder • Lipo NR *Seeking Health* (10% off: Richard10) https://crrnt.app/SEEK/-dm0MyrQ, Histamine Nutrients https://crrnt.app/SEEK/EpM7paAO *Stemregen* (15% off: MODERN) *US only* https://tinyurl.com/45z968yr *AX3 Life* (20% off: MODERN20) https://ax3.life/MODERN20 - Astaxanthin *n1o1* (10% off: Modern) https://tidd.ly/3IczGRW - Nitric Oxide Lozenges *Qualia* (15% off: MODERN) Creatine+ https://tinyurl.com/mr3z35jd Senolytic https://bit.ly/4jlaibe *Wellness Extract* (10% off: MODERNWE) http://wellnessextract.com/RICHARDWE Geranylgeraniol • Vit E ~~~~~~~~~~~~~~ For more than a decade, geroscience attributed rapamycin's life-extension benefits primarily to nutrient sensing, protein synthesis inhibition, and bulk autophagy. However, a groundbreaking 2026 study published in Aging Cell from the University of Oxford and the University of Nottingham reveals a previously unrecognized mechanism: rapamycin acts as a direct genoprotector. In this video, we examine laboratory evidence showing that low-dose rapamycin reduces DNA double-strand breaks by over 40% in human T cells challenged with severe genotoxic stress. We explore why this protective effect operates independently of autophagy, and we analyze the results from an attached 4-month, placebo-controlled human trial (NCT05414292) in older adults. The trial data confirms significant target engagement, clearance of p21 senescence markers, and reversal of inhibitory T-cell exhaustion markers (KLRG1 and NKG2A) without causing systemic immunosuppression. Finally, we connect these discoveries to the Mannick clinical trials and outline translational applications in radioprotection and viral resilience. 00:00 The Autophagy Dogma vs Direct Genoprotection 01:48 Aging Immune Cells & The mTORC1-DNA Damage Link 03:20 Breakthrough Mechanism: How Rapamycin Shields DNA 04:28 4-Month Human Clinical Trial Results (NCT05414292) 06:55 Explaining the Mannick Paradox & Viral Resilience 07:52 Summary & Clinical Applications of Genoprotection #Rapamycin #ImmuneAging #Longevity Disclaimer: The information provided in this video is for educational and informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or personal health protocol. Scientific References: - Primary Study (Oxford & Nottingham): Kell, L., Jones, E. J., Gharahdaghi, N., Wilkinson, D. J., Smith, K., Atherton, P. J., Alsaleh, G., et al. (2026). Rapamycin exerts its geroprotective effects in the ageing human immune system by enhancing resilience against DNA damage. Aging Cell, 25(2): e70364. https://doi.org/10.1111/acel.70364 - Human In Vivo Clinical Trial: Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle and Immune Senescence. ClinicalTrials.gov Identifier: NCT05414292 (https://clinicaltrials.gov/study/NCT05414292) - mTOR & Immune Function Trial 1: Mannick, J. B., et al. (2014). mTOR inhibition improves immune function in the elderly. Science Translational Medicine, 6(268): 268ra179. https://doi.org/10.1126/scitranslmed.3009892 - mTOR & Viral Infection Trial 2: Mannick, J. B., et al. (2018). TORC1 inhibition enhances immune function and reduces infections in the elderly. Science Translational Medicine, 10(449): eaaq1564. https://doi.org/10.1126/scitranslmed.aaq1564